Variational AI, through its Enki™ platform, leverages generative AI to create novel and diverse drug-like small molecules. This cutting-edge technology allows for rapid optimization of multiple properties necessary to produce effective drugs, thereby speeding up the drug discovery process. Variational AI aims to redefine the economics of drug development, minimizing time and costs while maximizing the potential for discovering life-saving treatments. Collaborating closely with biopharmaceutical companies, they are pioneering a new era in drug discovery.

GNS Healthcare uses advanced AI and multi-omics data to identify precise medical interventions and discover breakthrough drugs. Their technology creates Gemini Digital Twins from patient data to uncover hidden disease mechanisms, enabling personalized treatment and accelerated drug development. By integrating robust data analytics and machine learning algorithms, GNS transforms healthcare with actionable insights, improving patient outcomes and driving innovation in pharmaceutical research.